BridgeBio Oncology Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 0.0% | 0.0% | -12.5% |
| FY2024 | 41.6% | 41.6% | -45.2% |
| FY2025 | -32.6% | -32.6% | -29.9% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 0.0% | 0.0% | -12.5% |
| FY2024 | 41.6% | 41.6% | -45.2% |
| FY2025 | -32.6% | -32.6% | -29.9% |